Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma

PURPOSE: Objective responses are reported in 34% to 37% of patients with programmed death-1 (PD-1)–naïve advanced melanoma treated with PD-1 inhibitors. Pre-existing CD8+ T-cell infiltrate and interferon (IFN) gene signature correlate with response to PD-1 blockade. Here, we report a phase Ib/II stu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Davar, Diwakar, Wang, Hong, Chauvin, Joe-Marc, Pagliano, Ornella, Fourcade, Julien J., Ka, Mignane, Menna, Carmine, Rose, Amy, Sander, Cindy, Borhani, Amir A., Karunamurthy, Arivarasan, Tarhini, Ahmad A., Tawbi, Hussein A., Zhao, Qing, Moreno, Blanca H., Ebbinghaus, Scott, Ibrahim, Nageatte, Kirkwood, John M., Zarour, Hassane M.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2018
Témata:
Original Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6286160/
https://ncbi.nlm.nih.gov/pubmed/30359157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.00632
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky